---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-002216"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:12:31.464967+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition Corp completes merger with Estrella Biopharma; becomes Estrella Immunopharma, listing on Nasdaq

## Summary
- Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.
- Gross proceeds of ~$23.11M from PIPE ($10M) and Series A sales ($9.75M); funds expected to support operations into 2024.
- Officers/directors own ~92.3% of outstanding shares; former UPTD holders own ~4.8%.
- Common stock (ESLA) and warrants (ESLAW) start trading on Nasdaq on Oct 2, 2023.
- Entered into $50M equity line with White Lion Capital; 3.5M shares authorized under 2023 Incentive Plan.

## SEC filing metadata
- accession: 0001013762-23-002216
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 1.01, 2.03, 3.02, 9.01, 3.01, 3.03, 5.03, 5.01, 5.02, 5.05, 5.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/ea185637-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-002216
- JSON: https://secwatch.observer/filing/0001013762-23-002216.json
- Plain text: https://secwatch.observer/filing/0001013762-23-002216.txt

## Key facts
- Governance Changes
  Estrella Immunopharma, Inc.: New amended and restated bylaws (New Bylaws) approved and adopted by board of directors, effective as of the Effective Time (September 29, 2023) (effective 2023-09-29).
  - Change: bylaw amendment
  - Effective: 2023-09-29
  source text: On September 29, 2023, the board of directors of New Estrella approved and adopted the New Bylaws, which became effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
- Governance Changes
  Estrella Immunopharma, Inc.: Board of directors approved and adopted a new Code of Ethics applicable to directors, officers and employees in connection with the Closing (effective 2023-09-29).
  - Change: code of ethics
  - Effective: 2023-09-29
  source text: In connection with the Closing, the board of directors of New Estrella approved and adopted a new Code of Ethics applicable to directors, officers and employees.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
- Governance Changes
  Estrella Immunopharma, Inc.: Amended and restated certificate of incorporation (New Charter) approved at special meeting and effective upon filing with Secretary of State of Delaware on September 29, 2023 (effective 2023-09-29).
  - Change: charter amendment
  - Effective: 2023-09-29
  source text: The New Charter, which became effective upon filing with the Secretary of State of the State of Delaware on September 29, 2023, includes the amendments proposed by the Charter Proposal and approved at the Special Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
- Governance Changes
  Estrella Immunopharma, Inc.: Upon the Closing, New Estrella ceased to be a shell company.
  - Change: shell status
  source text: Upon the Closing, New Estrella ceased to be a shell company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
- M&A Transactions
  Estrella Immunopharma, Inc. underwent a change of control involving TradeUP Acquisition Corp. for $325,000,000 (closed 2023-09-29).
  - Action: change of control
  - Counterparty: TradeUP Acquisition Corp.
  - Consideration: $325,000,000
  - Closing: 2023-09-29
  source text: from UPTD, in the aggregate, a number of newly issued shares of common stock of New Estrella (as defined below), par value $0.0001 per share (“Common Stock”) equal to: (i) $325,000,000 (the “Merger Consideration”), divided by (ii) $10.00 per share (such shares of Common Stock is referred as “Merger Consideration Shares”) in consideration of converting their
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.